PLASMA LIPOPROTEINS AND FAMILIAL HYPERCHOLESTEROLEMIA
Introduction
Plasma lipoproteins are particles that transport lipids, including cholesterol, in the bloodstream. They are composed of proteins, phospholipids, cholesterol, and triglycerides. The main types of plasma lipoproteins are chylomicrons, very-low-density lipoproteins (VLDL), low-density lipoproteins (LDL), and high-density lipoproteins (HDL).
Familial hypercholesterolemia is a genetic disorder characterized by high levels of LDL cholesterol in the blood. It is caused by mutations in specific genes that regulate the clearance of LDL cholesterol from the bloodstream. These mutations can result in defective or insufficient LDL receptors on the surface of cells, leading to reduced uptake of LDL particles and increased circulating LDL cholesterol.
Individuals with familial hypercholesterolemia are at a higher risk of developing early-onset cardiovascular diseases, such as coronary artery disease and atherosclerosis, due to the accumulation of LDL cholesterol in blood vessels.
Treatment for familial hypercholesterolemia often includes lifestyle changes, such as a heart-healthy diet and regular exercise, along with medications like statins to lower LDL cholesterol levels. In some cases, additional therapies like LDL apheresis or PCSK9 inhibitors may be used to further manage cholesterol levels. Genetic testing and early diagnosis are crucial in managing this condition effectively.
Lipoproteins: Structure & Functions
Lipoproteins are complex particles composed of lipids (such as cholesterol and triglycerides) and proteins. They play a crucial role in transporting lipids through the bloodstream since lipids are not water-soluble. There are several types of lipoproteins, each with unique functions and compositions:
- Chylomicrons: These are the largest and least dense lipoproteins, formed in the intestinal cells after the absorption of dietary fats. They transport dietary triglycerides from the intestines to various tissues, including adipose tissue and muscle, where they are either stored or used as an energy source.
- Very-Low-Density Lipoproteins (VLDL): VLDLs are produced in the liver and contain a higher proportion of triglycerides compared to other lipoproteins. They transport endogenous triglycerides from the liver to various tissues, contributing to energy storage and lipid metabolism.
- Intermediate-Density Lipoproteins (IDL): IDLs are transient particles formed during the metabolism of VLDLs. They can either be converted into low-density lipoproteins (LDLs) or taken up by the liver.
- Low-Density Lipoproteins (LDL): Often referred to as “bad cholesterol,” LDLs are rich in cholesterol and are formed from the metabolism of IDLs. Their primary function is to deliver cholesterol to peripheral tissues, including the arterial walls. However, excessive LDL levels can lead to atherosclerosis and an increased risk of cardiovascular diseases.
- High-Density Lipoproteins (HDL): Known as “good cholesterol,” HDLs have a higher protein content and are involved in the reverse cholesterol transport pathway. They collect excess cholesterol from tissues and transport it back to the liver for excretion or recycling. This helps maintain a healthy balance of cholesterol in the body.
The various functions of apoproteins, which are protein components of lipoproteins, are as follows:
- Stabilization: Apoproteins provide structural stability to lipoprotein particles, ensuring their integrity during transportation in the bloodstream.
- Ligand binding: Apoproteins act as ligands for cell surface receptors, enabling the uptake of lipoproteins by target tissues. For example, apolipoprotein B-100 (apoB-100) is the main ligand for LDL receptors.
- Enzyme activation: Some apoproteins act as cofactors for enzymes involved in lipid metabolism. For instance, apolipoprotein C-II (apoC-II) activates lipoprotein lipase, an enzyme responsible for hydrolyzing triglycerides in chylomicrons and VLDLs, releasing free fatty acids for cellular uptake.
- Lipid transfer: Apoproteins mediate the exchange of lipids between different lipoprotein classes, facilitating lipid redistribution and metabolic regulation.
Understanding the structure, components, and functions of lipoproteins is essential in comprehending their impact on overall health and the development of cardiovascular diseases. Proper regulation of lipoprotein metabolism is crucial for maintaining a healthy lipid profile and reducing the risk of heart-related issues.
Metabolic pathway of chylomicrons, VLDL, LDL, and HDL
- Chylomicrons: Chylomicrons are large lipoprotein particles synthesized in the intestinal mucosa after the absorption of dietary fats. These particles transport dietary triglycerides and other lipids from the small intestine to the rest of the body tissues. Chylomicrons are released into the lymphatic system and eventually enter the bloodstream. In the peripheral tissues, an enzyme called lipoprotein lipase (LPL) hydrolyzes the triglycerides present in chylomicrons, releasing free fatty acids that can be taken up by cells for energy or storage.
- VLDL (Very-Low-Density Lipoprotein): VLDL is another type of lipoprotein synthesized in the liver. It mainly carries endogenously synthesized triglycerides along with some cholesterol and other lipids. Once released into the bloodstream, VLDL particles interact with lipoprotein lipase (LPL) on the surface of blood vessels, similar to chylomicrons, leading to the hydrolysis of triglycerides and the release of free fatty acids to be used by various tissues. As triglycerides are removed, VLDL particles shrink and eventually become intermediate-density lipoproteins (IDL).
- LDL (Low-Density Lipoprotein): IDL further loses triglycerides and transforms into LDL, which is primarily composed of cholesterol. LDL is often referred to as “bad cholesterol” because excessive LDL levels in the bloodstream can lead to the accumulation of cholesterol in arteries, increasing the risk of atherosclerosis and cardiovascular diseases. LDL particles are taken up by various cells in the body through specific receptors, particularly in the liver and peripheral tissues. The excess accumulation of LDL in the arterial walls can lead to the formation of plaques.
- HDL (High-Density Lipoprotein): HDL is known as “good cholesterol” because it plays a crucial role in the reverse cholesterol transport pathway. HDL particles are synthesized in the liver and intestine and then released into the bloodstream. They collect excess cholesterol from tissues, including arterial walls, and transport it back to the liver for excretion or recycling. HDL acts as a protective mechanism, reducing the risk of atherosclerosis by removing excess cholesterol from arterial walls and preventing the formation of plaques.
These metabolic pathways are essential for maintaining lipid balance in the body and are influenced by various factors, including diet, genetics, and lifestyle choices. Proper regulation of these pathways is critical for overall health and the prevention of cardiovascular diseases.
Familial hypercholesterolemia biochemical basis
Familial hypercholesterolemia (FH) is a genetic disorder that affects how the body processes cholesterol. It is characterized by extremely high levels of low-density lipoprotein (LDL) cholesterol in the blood, leading to an increased risk of early-onset cardiovascular diseases, such as heart attacks and strokes.
The primary biochemical basis of FH lies in mutations in certain genes that encode proteins involved in cholesterol metabolism. The most common genes affected in FH are the LDL receptor (LDLR) gene, apolipoprotein B (APOB) gene, and proprotein convertase subtilisin/kexin type 9 (PCSK9) gene.
- LDL Receptor (LDLR) Gene: The LDL receptor is responsible for removing LDL cholesterol from the bloodstream by binding to it and transporting it into cells. Mutations in the LDLR gene lead to reduced or non-functional receptors, resulting in impaired LDL cholesterol uptake by cells. As a result, LDL cholesterol accumulates in the blood, leading to hypercholesterolemia.
- Apolipoprotein B (APOB) Gene: Apolipoprotein B is an essential component of LDL particles. Mutations in the APOB gene can result in the production of abnormal LDL particles that have a reduced affinity for the LDL receptor, leading to decreased clearance of LDL cholesterol from the blood.
- Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gene: PCSK9 is a protein that regulates the number of LDL receptors on the cell surface. Mutations in the PCSK9 gene can lead to increased levels of PCSK9, which, in turn, results in more rapid degradation of LDL receptors. This leads to decreased LDL cholesterol uptake by cells and contributes to hypercholesterolemia.
In FH, the impaired ability to remove LDL cholesterol from the blood results in its accumulation and deposition in arterial walls, leading to the development of atherosclerotic plaques. These plaques can narrow and block blood vessels, increasing the risk of cardiovascular events.
FH can be inherited in an autosomal dominant manner, meaning that if one parent carries the mutated gene, there is a 50% chance of passing it on to each child. It is important to diagnose and manage FH early to prevent cardiovascular complications through lifestyle modifications, medication, and sometimes, LDL apheresis or liver transplantation in severe cases.
You May Also Like
INCREASED MINUTE VENTILATION DURING PREGNANCY IS DUE TO
RIVER REGIMES
